Pfizer is adopting a direct-to-consumer approach similar to Eli Lilly's strategy, aiming to sell medications such as Paxlovid and migraine nasal spray directly online, bypassing traditional industry middlemen. This shift reflects a broader trend within the pharmaceutical sector towards simplifying distribution processes and reducing associated costs, particularly for high-demand treatments like obesity medications. Pfizer plans to launch its online platform by year-end, connecting patients with consultants for prescriptions and utilising suppliers for filling and shipping orders.
Despite facing a significant 20% decline in sales in the first quarter, Pfizer managed to surpass analyst expectations, resulting in a notable surge in its stock price. While sales of COVID products notably decreased, excluding these, Pfizer experienced an 11% increase in overall sales. The company reaffirmed its revenue guidance for the year and maintained its 2023 sales estimates for key COVID products like Comirnaty and Paxlovid. Additionally, Pfizer saw substantial growth in sales of other key products like Eliquis and Vyndaqel, though challenges such as upcoming generic competition and loss of exclusivity remain areas of concern.
Furthermore, Pfizer is attentive to potential legislative impacts such as the Inflation Reduction Act on its product pricing and market performance. The company is also focused on leveraging recent acquisitions, like Seagen, to expand its product portfolio and drive future revenue growth. Despite market fluctuations and looming challenges, Pfizer remains committed to diversifying its distribution channels and optimising its product portfolio to sustain growth in the dynamic pharmaceutical market.
Click here to read the original news story.